These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30043734)

  • 1. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells].
    Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
    Dai J; Huang Q; Niu K; Wang B; Li Y; Dai C; Chen Z; Tao K; Dai J
    Cancer Med; 2018 Nov; 7(11):5691-5703. PubMed ID: 30311444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
    Wu J; Chai H; Li F; Ren Q; Gu Y
    Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
    Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
    Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma.
    Chen L; Wang L; Han Z; Qin P; Niu G; Du J
    Tohoku J Exp Med; 2024 Mar; 262(3):173-180. PubMed ID: 38123304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
    Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
    Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Y-box binding protein 1 augments sorafenib resistance
    Liu T; Xie XL; Zhou X; Chen SX; Wang YJ; Shi LP; Chen SJ; Wang YJ; Wang SL; Zhang JN; Dou SY; Jiang XY; Cui RL; Jiang HQ
    World J Gastroenterol; 2021 Jul; 27(28):4667-4686. PubMed ID: 34366628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.
    Xiang QF; Zhan MX; Li Y; Liang H; Hu C; Huang YM; Xiao J; He X; Xin YJ; Chen MS; Lu LG
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):83-89. PubMed ID: 30663411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway.
    Tan G; Xie B; Yu N; Huang J; Zhang B; Lin F; Li H
    Int J Clin Oncol; 2021 Mar; 26(3):532-542. PubMed ID: 33387087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
    Liu J; Qiu WC; Shen XY; Sun GC
    Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid hormone T3 augments the cytotoxicity of sorafenib in Huh7 hepatocellular carcinoma cells by suppressing AKT expression.
    Uyulgan S; Köse SN; Kıpçak A; Başkan Y; Dağlar G; Karagonlar ZF; Yandım C
    J Cancer Res Ther; 2024 Apr; 20(3):755-762. PubMed ID: 39023579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.